Department of Radiotherapy, Regensburg University Medical Center, D-93042 Regensburg, Germany.
Radiat Oncol. 2010 Oct 25;5:95. doi: 10.1186/1748-717X-5-95.
The purpose of this study was to assess plan quality and treatment time achievable with the new VMAT optimization tool implemented in the treatment planning system Oncentra MasterPlan® as compared to IMRT for Elekta SynergyS® linear accelerators.
VMAT was implemented on a SynergyS® linear accelerator (Elekta Ltd., Crawley, UK) with Mosaiq® record and verify system (IMPAC Medical Systems, Sunnyvale, CA) and the treatment planning system Oncentra MasterPlan® (Nucletron BV, Veenendaal, the Netherlands). VMAT planning was conducted for three typical target types of prostate cancer, hypopharynx/larynx cancer and vertebral metastases, and compared to standard IMRT with respect to plan quality, number of monitor units (MU), and treatment time.
For prostate cancer and vertebral metastases single arc VMAT led to similar plan quality as compared to IMRT. For treatment of the hypopharynx/larynx cancer, a second arc was necessary to achieve sufficient plan quality. Treatment time was reduced in all cases to 35% to 43% as compared to IMRT. Times required for optimization and dose calculation, however, increased by a factor of 5.0 to 6.8.
Similar or improved plan quality can be achieved with VMAT as compared to IMRT at reduced treatment times but increased calculation times.
本研究旨在评估新的 VMAT 优化工具在 Elekta SynergyS®直线加速器上的应用效果,并将其与 IMRT 进行比较,评估其计划质量和治疗时间的可实现性。
在配备 Mosaiq®记录和验证系统(IMPAC Medical Systems,加利福尼亚州森尼韦尔)和治疗计划系统 Oncentra MasterPlan®(荷兰 Nucletron BV)的 SynergyS®直线加速器上实施 VMAT。针对前列腺癌、下咽/喉癌和椎体转移三种典型的靶区类型进行 VMAT 计划,并与标准的 IMRT 计划进行比较,比较内容包括计划质量、机器跳数(MU)和治疗时间。
对于前列腺癌和椎体转移,与 IMRT 相比,单弧 VMAT 可获得相似的计划质量。对于下咽/喉癌的治疗,需要第二个弧才能达到足够的计划质量。与 IMRT 相比,所有病例的治疗时间均缩短至 35%至 43%。然而,优化和剂量计算所需的时间增加了 5.0 至 6.8 倍。
与 IMRT 相比,VMAT 可实现相似或更好的计划质量,并缩短治疗时间,但计算时间会增加。